Companies › Entrada Therapeutics
1 active drug program in 2 registered trials: 2 Phase 1; Neurology; next expected readout Mar 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ENTR-601-45 Antisense oligonucleotide for exon 45 skipping in DMD | – | Phase 1 | Duchenne Muscular Dystrophy (DMD) | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07038824 | ENTR-601-45 | Phase 1 | Duchenne Muscular Dystrophy (DMD) | Neurology | Mar 2029 |
| NCT07037862 | ENTR-601-45 | Phase 1 | Duchenne Muscular Dystrophy (DMD) | Neurology | Mar 2029 |
Cash and short-term investments of $193m on 2026-09-30; operating cash outflow about $140m a year; runway about 17 months at that burn, to Feb 2028
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.